This study identifies four molecular subtypes within HR+/HER2+ #BreastCancer and shows how their distinct biology guides tailored therapies, from intensified #antiHER2 regimens to ER–HER2 targeting, ADCs, #immunotherapy, and #PI3Kinhibitors.

#OpenAccess #STTT: doi.org/10.1038/s413...